Ultime notizie per Gyre Therapeutics (NASDAQ:GYRE) Azioni

Gyre Therapeutics

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics Inc

Baird analyst Timothy Wojs maintains Fortune Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBIN#NYSE">FBIN</a>) with a Neutral and lowers the price target from $94 to $90.

News

Price Target

Analyst Ratings

FBIN

Baird Maintains Neutral on Fortune Brands, Lowers Price Target to $90

US Foods Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>) reported third-quarter adjusted earnings per share of 85 cents,<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41801904/us-foods-reports-third-quarter-fiscal-year-2024-earnings" rel="noreferrer noopener"> beating the street view of 83 cents.</a> Quarterly sales of $9.728 billion (+6.8%) outpaced the analyst consensus estimate of $9.718 billion,&nbsp;driven by total case volume growth and food cost inflation of 3.2%.
&#8220;We delivered strong results in the&nbsp;third quarter&nbsp;despite the softer macro environment and weather-related challenges which pressured industry case volumes,&#8221; said Dave Flitman, CEO.
In its latest quarterly earnings, US Foods reported a 3.8% increase in total case volume, with independent restaurant case volume rising by 4.1%. The company&#8217;s gross profit grew by 8.1%, reaching $1.7 billion.
Net income for the quarter was $148 million, while adjusted EBITDA increased 13.2% to $455 million.
Adjusted gross profit was $1.7 billion, an increase of 7.0% from the prior year. Adjusted gross profit as a percentage of net sales was 17.4%.
Also Read:<a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41812800/papa-johns-earns-less-dough-as-q3-sales-dip-ceo-blames-challenging-consumer-environment" rel="noreferrer noopener"> Papa John&#8217;s Earns Less Dough As Q3 Sales Dip, CEO Blames &#8216;Challenging Consumer Environment&#8217;</a>
Net debt at the end of the third quarter of fiscal year 2024 was $4.7 billion. The company exited the quarter with cash and equivalents worth $81 million. Long-term debt as of quarter-end totaled $4.671 billion.
At the end of the third quarter, the company had approximately $398 million in remaining funds authorized under its $1 billion share repurchase program.
&#8220;In the face of the softer macro backdrop, we continue to grow sales, expand margins and deploy our strong free cash flow,&#8221; said Dirk Locascio, CFO. &#8220;Additionally, we allocated $580 million of capital during the quarter toward share repurchases while maintaining a strong balance sheet.&#8221;
Outlook: US Foods Holding tightened its FY24 net sales outlook to $37.7 billion &#8211; $38.0 billion, compared to the prior view of $37.5 billion &#8211; $38.5 billion and the <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst estimate of $37.84 billion.</a>
The company also projects adjusted diluted earnings per share of $3.05 &#8211; $3.15, narrower than the prior view of $3.00 &#8211; $3.20, compared with the $3.08 estimate.
Price Action: USFD shares are trading higher by 0.36% to $66.04&nbsp;at last check Thursday.
Also Read:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41806970/hersheys-q3-earnings-sour-as-sales-dip-and-outlook-darkens-ceo-pledges-aggressive-turnaround-amid-h" target="_blank" rel="noreferrer noopener">Hershey&#8217;s Q3 Earnings Sour As Sales Dip And Outlook Darkens; CEO Pledges Aggressive Turnaround Amid High Cocoa Costs</a></li>
</ul>

Earnings

Equities

Guidance

Markets

General

USFD

US Foods Beats Q3 Expectations As Sales And Case Volumes Surge, Tightens FY24 Outlook

Baird analyst David Tarantino maintains Dutch Bros (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) with a Neutral and raises the price target from $37 to $46.

BROS

Baird Maintains Neutral on Dutch Bros, Raises Price Target to $46

<a href="https://www.gevernova.com/news/press-releases/ge-vernova-expands-strategic-collaboration-agreement-aws-help-energy-companies" title="https://www.gevernova.com/news/press-releases/ge-vernova-expands-strategic-collaboration-agreement-aws-help-energy-companies">https://www.gevernova.com/news/press-releases/ge-vernova-expands-strategic-collaboration-agreement-aws-help-energy-companies</a>

AMZN

GE Vernova Expands Collaboration With AWS To Accelerate Energy Transition, Integrating Asset Performance Management And CERius Software On AWS Cloud

Nexstar Media Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXST#NASDAQ">NXST</a>) shares are trading higher. The company reported a third-quarter fiscal year 2024 net revenue increase of 20.7% year over year to $1.366 billion. That&#8217;s <a href="https://www.benzinga.com/pressreleases/24/11/b41802369/nexstar-media-group-reports-record-third-quarter-net-revenue-of-1-37-billion" target="_blank" rel="noreferrer noopener">in line with the consensus</a>.
<ul>
<li>Revenues from Advertising rose&nbsp;22.2% to&nbsp;$622 million. The growth was led by a $135 million year-over-year rise in election-year political advertising.</li>
<li>Distribution revenue gained&nbsp;20.2% to&nbsp;$719&nbsp;million. This growth was driven by the resolution of a 2023 MVPD dispute, favorable contract renewals, annual rate increases, higher vMVPD subscribers, new CW affiliations, and the return of partner stations.</li>
<li>Adjusted EBITDA jumped&nbsp;82.8% Y/Y to&nbsp;$510 million, and the margin expanded to&nbsp;37.3% from&nbsp;24.6% a year ago.</li>
<li>EPS was&nbsp;$5.27, up from&nbsp;$0.70 in the prior year quarter but&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">below the consensus of&nbsp;$5.40.</a></li>
<li>Adjusted free cash flow totaled&nbsp;$327 million, up from&nbsp;$81 million in the prior year quarter. As of September 30, 2024, unrestricted cash stood at&nbsp;$181 million.</li>
</ul>
Buyback: The company repurchased shares worth $178&nbsp;million in the quarter. The company announced a new $1.5 billion share repurchase authorization in July 2024.
Nexstar CEO Perry A. Sook said, &#8221;During the quarter, we made further progress on our strategy for The CW, reducing operating losses by $36 million year-over-year and by $119 million year-to-date.&#8221;
&#8221;We debuted NASCAR Xfinity Series racing in September and WWE NXT wrestling in October on The CW broadcast network to double-digit percentage increases both in total audience and in adults 18-49 versus previous viewership on cable.&#8221;
Investors can gain exposure to the stock via&nbsp;LeaderShares AlphaFactor Tactical Focused ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSAT#NYSE">LSAT</a>) and Northern Lights Fund Trust IV Monarch Dividend Plus Index ETF (MDPL).
Price Action: Nexstar shares are up 2.92% at $188.60 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41815459" target="_blank" rel="noreferrer noopener">Rockwell Automation&#8217;s Mixed&nbsp;Q4: EPS&nbsp;Beats&nbsp;Amid 21%&nbsp;Sales Drop And Cautious FY25&nbsp;Outlook</a></li>
</ul>
Image:

Mid Cap

LSAT

NXST

Nexstar Media Q3: Political Ads, Distribution Gains Drive 21% Revenue Growth

Donald Trump's 2024 presidential win could prompt his hush money trial sentencing to be dismissed before the <a href="https://www.benzinga.com/general/politics/24/09/40754802/trump-hush-money-sentencing-will-now-take-place-after-2024-election-to-avoid-any-appearance-to-a">scheduled Nov. 26 date.</a>
What Happened: Trump <a href="https://www.benzinga.com/general/politics/24/05/39100065/trump-found-guilty-on-all-34-counts-in-hush-money-criminal-trial-heres-what-happens-next">was found guilty </a>on 34 counts of falsified business records in May in a New York trial known as the hush money trial.
Key witness testimony from former lawyer Michael Cohen and adult actress Stormy Daniels led to the 12-person jury finding Trump guilty on all 34 counts.
Sentencing was originally planned for July, but <a href="https://www.benzinga.com/general/politics/24/07/39609026/donald-trump-hush-money-trial-sentencing-delayed-to-september-18-the-supreme-court-immunity-impa">was delayed </a>by Judge Juan Merchan to Sept. 18 due to a Supreme Court ruling that granted partial immunity to Trump.
Judge Merchan postponed the sentencing from September to Nov. 26 to distance the trial from the 2024 election.
With Trump winning, legal experts now believe Merchan will call off the sentencing.
"I think any reasonable judge wouldn't sentence the president-elect," retired New York trial judge Jill Konviser said, as <a href="https://www.politico.com/news/2024/11/06/trump-sentencing-probably-wont-happen-00187999">reported </a>by Politico.
Set to be inaugurated as president in January, legal experts say Trump could argue that any sentencing, whether it be jail, home confinement or community service would interfere with his upcoming presidential duties.
Former Manhattan assistant district attorney Jeremy Saland doesn't see the sentencing moving ahead.
"The former president/president-elect does not get sentenced," Saland told Politico.
Former prosecutor Neama Rahmani said Merchan may not "have the stomach to imprison a former president or president-elect,&#8221; as <a href="https://nypost.com/2024/11/07/us-news/judge-in-trumps-hush-money-trial-considers-tossing-felony-conviction/">reported </a>by the New York Post. 
"Now that Trump has won, his criminal problems go away," Rahmani said.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent110724">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
What's Next: Judge Merchan will be tasked with sentencing in the case if nothing changes. Each of the 34 counts of which Trump was found guilty comes with a punishment of up to four years in prison. Trump is unlikely to receive prison time due to having no criminal record.
The sentence is also <a href="https://www.usatoday.com/story/news/factcheck/2024/05/31/trump-prison-time-fact-check/73916922007/">limited </a>to the total number of years Trump could face in prison, with New York limiting consecutive sentences for Class E felonies to a maximum of 20 years.
While he may not face prison time, a sentence of probation or home confinement could still occur and come ahead of inauguration day.
One option for Merchan would be to continue with the planned sentencing on Nov. 26 and any ruling would be deferred until 2029 when Trump is out of the White House. Merchan could also delay the sentencing until Trump is out of office.
The hush money trial is not the only case against Trump, with three other criminal cases currently pending. Each of these cases could also be closed after Trump's 2024 election victory.
Merchan also has to rule on a request by Trump for the guilty verdict to be thrown out after the Supreme Court ruling on presidential immunity. That ruling is currently scheduled for Nov. 12 and could make the Nov. 26 sentencing a non-issue.
While any prison sentence would complicate Trump&#8217;s presidency, there are <a href="https://www.benzinga.com/news/23/07/33446444/donald-trump-will-still-run-for-president-if-convicted-and-right-now-thats-perfectly-legal" target="_blank" rel="noopener">no current rule</a><a href="https://www.benzinga.com/news/23/07/33446444/donald-trump-will-still-run-for-president-if-convicted-and-right-now-thats-perfectly-legal">s</a> against running for president or even being president if incarcerated.
Trump <a href="https://www.benzinga.com/m-a/23/08/33878846/trump-to-maintain-control-of-media-company-if-he-sells-majority-goes-to-jail-or-becomes-president">will also maintain control </a>of his company Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) if he is sentenced to prison.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/11/41784933/donald-trumps-wealth-soars-with-2024-election-win-heres-how-much-president-elect-is-worth-ho">Donald Trump&#8217;s Wealth Soars With 2024 Election Win: Here&#8217;s How Much President-Elect Is Worth, How Much He&#8217;ll Make In White House</a></li>
</ul>
Photo: Shutterstock

Politics

Legal

Will Trump Be Sentenced In Hush Money Trial Or Will His 'Criminal Problems Go Away'?

WIIM

TRNR

Interactive Strength shares are trading lower after the company announced a 1-for-100 reverse split.

Wendy&#8217;s Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) is using artificial intelligence from data analytics firm Palantir Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) to manage its supply of <a href="https://www.benzinga.com/general/restaurants/24/10/41149776/wendys-is-ready-kids-and-adults-spongebob-squarepants-collaboration-includes-pineapple-frosty">burgers, fries and Frosty's.</a> 
The Details: Wendy's supply chain purchases are handled by an independent co-op group that first tested Palantir's technology last year amid tight profit margins and increasing pressure from inflation, according to a Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-11-07/wendy-s-wen-1-frosty-deal-made-easier-with-ai-from-palantir-pltr?sref=TBDibEcD">report.</a> The group is using Palantir's system to spot shortages and suggest solutions like placing an order from a supplier. 
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
Pete Suerken, who leads the purchasing co-op, said the system's AI learns over time and can suggest a specific warehouse, after considering factors such as cost and the probability of the items arriving on time. The software <a href="https://www.benzinga.com/markets/equities/24/08/40220301/whats-going-on-with-palantir-stock-today">can predict</a> when specific products will run out by analyzing current and historical sales figures.&nbsp;
Suerken praised Palantir's platform and said it was "so much better" than spreadsheets and other customary inventory management methods. He also said the return on investment is "significant." 
Wendy's recently asked the supply chain program to identify shortages restaurants could face over the following three weeks and then staff trained the model by showing how the shortages should be solved. Wendy's purchasing group plans to eventually allow the AI model to manage smaller inventory and ordering tasks autonomously and without human intervention. 
"Three or four years from now, if you're not doing this, you'll be at a distinct disadvantage," said Suerken. "This is something that, as an industry, will change the way we work."&nbsp;
WEN, PLTR Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Wendy's shares are down 1.54% at $20.08 and Palantir shares are down 2.13% at $54.32 at the time of publication Thursday. 
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41561955/dollar-general-aims-to-draw-customers-from-walmart-amazon-with-holiday-sales-events">Dollar General Aims To Draw Customers From Walmart, Amazon With Holiday Sales Events</a></li>
</ul>
Photo: Shutterstock

Restaurants

Tech

PLTR

Wendy's Uses Palantir AI Tech To Manage Burger, French Fry Inventories; Return On Investment Is 'Significant'

Lion Electric shares are trading lower after the company reported worse-than-expected Q3 financial results.

RBC Capital analyst Piral Dadhania maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Sector Perform and lowers the price target from $82 to $80.

RBC Capital Maintains Sector Perform on Nike, Lowers Price Target to $80

CHRS

Coherus BioSciences shares are trading higher after the company reported better-than-expected Q3 financial results.

BRDG

Bridge Investment Group shares are trading lower after the company reported worse-than-expected Q3 adjusted EPS results.

IHRT

iHeartMedia shares are trading higher after the company announced better-than-expected Q4 sales guidance.

CEVA

CEVA shares are trading higher after the company reported better-than-expected Q3 financial results and approved an increase to the buyback program by 700k shares.

RBC Capital analyst Scott Heleniak maintains NMI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMIH#NASDAQ">NMIH</a>) with a Outperform and lowers the price target from $48 to $47.

NMIH

RBC Capital Maintains Outperform on NMI Holdings, Lowers Price Target to $47

Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.12) by 91.67 percent. The company reported quarterly sales of $70.77 million which beat the analyst consensus estimate of $59.23 million by 19.49 percent. This is a 5.09 percent decrease over sales of $74.57 million the same period last year.

Earnings Beats

Reported November 6: Coherus BioSciences Q3 2024 Adj EPS $(0.01) Beats $(0.12) Estimate, Sales $70.77M Beat $59.23M Estimate

AUPH

Aurinia Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results and announced a workforce reduction.

UPWK

Upwork shares are trading higher after multiple firms maintained Buy ratings on the stock and raised their respective price targets.

RBC Capital analyst Gregory Renza maintains Nuvation Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>) with a Outperform and raises the price target from $5 to $6.

NUVB

RBC Capital Maintains Outperform on Nuvation Bio, Raises Price Target to $6

Piper Sandler analyst Clarke Jeffries maintains PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) with a Neutral and raises the price target from $182 to $202.

Piper Sandler Maintains Neutral on PTC, Raises Price Target to $202

Gyre Therapeutics announces expected addition to Russell 2000 and Russell 3000 Indexes

Gyre Therapeutics files to sell 1.08M shares of common stock for holders

Gyre Therapeutics (GYRE) has issued an announcement. Gyre Therapeutics has announced the approval of its IND application by China's CDE for F230 ta...

Gyre Therapeutics Advances with F230 IND Approval in China

Suzhou MediLink partnered with Germany's BioNTech to use MediLink's TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in milestones, plus tiered royalties.

Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership

Week In Review: MediLink And BioNTech Form $1.8B ADC Partnership

Gyre Therapeutics (GYRE) has shared an announcement. Gyre Therapeutics, Inc. has reported a vacancy on its Audit Committee following the resignatio...

Gyre Therapeutics Seeks Compliance Amid Board Reshuffle

Gyre Therapeutics (GYRE) has issued an announcement. Gyre Therapeutics, Inc. has strengthened its leadership by appointing the highly experienced D...

Gyre Therapeutics Welcomes Dr. Epstein to Leadership Team

Gyre Therapeutics Non-GAAP EPS of $0.01, revenue of $25.2M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Gyre Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/gyre-stock-quote/">GYRE</a>) just reported results for the second quarter of 2024.<ul><li>Gyre Therapeutics reported earnings per share of 1 cent.</li><li>The company reported revenue of $25.23 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/gyre-stock-earnings-gyre-therapeutics-for-q2-of-2024/">GYRE Stock Earnings: Gyre Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GYRE Stock Earnings: Gyre Therapeutics Reported Results for Q2 2024

Gyre Therapeutics (GYRE) announced that the last patient in Gyre Pharmaceuticals' pivotal Phase 3 trial in the People's Republic of China or PRC ev...

Gyre: Last patient completes trial evaluating F351 for CHB-liver fibrosis

AHKSF

AHKSY

AKESF

BAYRY

BAYZF

BNTX

CALT

CLTEF

CSPHF

ESAIY

ESALF

GYRE

SMMT

Health Care

Press Releases

Gyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension

Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology

Gyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia

Management

Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Events

Sidoti Events, LLC's Virtual August Micro-Cap Conference

Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

Comments

Gyre Therapeutics

Notizie

Ultime notizie per Gyre Therapeutics (NASDAQ:GYRE) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO